Rockley Photonics Holdings Ltd (RKLYQ)

[Bruinfan4ever]

I really don't think White Box would buy Rockley.

But they do have the ability to short. They know long term the price is going up. But they can take advantage of these market conditions and low volume to short it down and make money that way.

[Nomadphotoguy]

Hedge fund (Whitebox Advisors) driving the stock price down so they can pick up cheap shares. That way the shareholders are thrilled to take a $11 buyout. That’s my take…

[Bruinfan4ever]

Did someone put out a short report on Rockley?

This sell off seems kind of strange. 20%?

Iceberg put one out on April 22. So I wouldn't be surprised.

Otherwise this could be dilution.

Strange there would be a 20% drop for no reason.

[SteveSchiets]

Great find guys. Looking forward how this will play out

[Bruinfan4ever]

I believe this is just a hedgefund though, taking an 11% stake in the company. On page 2.

https://whalewisdom.com/filer/whitebox-advisors-llc#tabholdings_tab_link

In 2019 Whitebox bet big on Remington.

https://www.hedgeco.net/news/11/2019/hedge-fund-whitebox-places-big-bet-on-gunmaker-remington.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+HedgeCo+%28HedgeCo+News%29

[Bruinfan4ever]

129 Million outstanding.

I believe this is the third photonics company the CEO has been in and I believe the other two were sold at ramp up.

So I would not be surprised if a buyout does happen.

I doubt there would be a takeover, but a buyout very possible.

Coke took a 15% stake in Bodyarmour before buying them out for 5.6 Billion

https://investors.coca-colacompany.com/news-events/press-releases/detail/1041/the-coca-cola-company-acquires-remaining-stake-in-bodyarmor

[prototype_101]

Wow, that's over 10% I believe there are 127 million shares O/S correct?? "Whitebox" is a generic term used when big players like Facebook or Amazon build there own Photonics devices in-house, I wonder if this is a smoke screen holding company for one of the big players preparing to do a takeover of RKLY on the cheap, maybe Apple?

[Bruinfan4ever]

13G Filed

White Box advisors holds over 14 Million shares.

https://d18rn0p25nwr6d.cloudfront.net/CIK-0001852117/5485c475-2c6a-41f8-bd19-8018a49e627a.pdf

[SteveSchiets]

Found it

https://wsw.com/webcast/baird64/rock.ph/2310588

[SteveSchiets]

Do you have a link Bruin? Thx

[Bruinfan4ever]

Very good Webinar this morning. Exciting stuff. They expect to break even by the end of 2023.

[Bruinfan4ever]

Rockley gave one company early access to the glucose monitor. I always assumed it was apple.

A new report coming from industry sources claims that Apple Watch Series 8 might get a blood glucose monitoring feature, reports MacRumors. For a while, the feature was rumored for the Apple Watch Series 7, but it didn't happen, and now industry sources are claiming it might happen with the Series 8.Apr 12, 2022

May find out on Monday as Apple releases news on all their new products.

[Bruinfan4ever]

Baird’s 2022 Global Consumer, Technology & Services Conference on Monday, June 6, 2022, at 8:30 a.m. ET

https://investors.rockleyphotonics.com/news/news-details/2022/Rockley-Photonics-to-Present-at-Bairds-2022-Global-Consumer-Technology--Services-Conference/default.aspx

[Bruinfan4ever]

New Presentation released today.

https://investors.rockleyphotonics.com/events-and-presentations/default.aspx

[Bruinfan4ever]

Blackrock and Vanguard taking positions in Rockley.

BLACKROCK INC. 03/31/2022 1,490,587 1,161,476 352.913% $3,920
VANGUARD GROUP INC 03/31/2022 1,280,371 1,229,155 2399.943% $3,367

[Bruinfan4ever]

Quin Bolton lowered his price target to 4.00.

I think he just wants to hit his target. He has been wrong over and over again.

[Bruinfan4ever]

Rockley just passed lightwave in percent gains which is incredible with the way the day started for both.

Nice call on the 2.12. You missed by one stick. LOL

[prototype_101]

Bruin, I agree, Rickman saying any competition is years behind in development, and although no guidance for 2023 forward on Revenue, personally I can't imagine it not being significant based on all of the news releases on the health monitoring platform being better than expected, and the major customer list growing from when those early guidance numbers of 300+ million were published in this SEC doc

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001852117/000185211722000157/rkly-20220512.htm

so the bad news of course is the PP but presumably that hit has been taken now in the PPS and the charts tell us that this stock has been in Accumulation for 6 months now already, so barring a complete market collapse I would think the bottom should be in at 2.12

Steve, your 1.50 target still alive? boy I sure hope not!

[Bruinfan4ever]

Yes, I like the fact that they feel they really have no competition. Just have to wait this out. But I am sure it will be worth it in the end.

[YearOfTheWorm]

Despite the tankfest, he did great imo. Some interesting new details emerged in the call; strongly suggest listening to it.

[Bruinfan4ever]

I just hope the CEO sounds confident on the conference all shortly.

[YearOfTheWorm]

IMO no surprise there. Cant expect to build Rome and then just walk away from building costs when the first sales come in. Must keep pushing progress further refining the hardware and algos/AI. Patience...

[Bruinfan4ever]

Wow it does show that. Thanks. But the bummer part is it looks like they still won't be profitable. Is that what I am seeing?

[YearOfTheWorm]

Yes, they DID give 2023 guidance this morning of $300M-$320M for 2023 as part of their Edgar filing. If the link below doesn't work, can just go to EDGAR, search for RKLY, and this morning's filing.

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001852117/000185211722000157/rkly-20220512.htm

Have to scroll to near the bottom; there is a table of projections.

[Bruinfan4ever]

In a presentation months ago, they had 400 million for 2023 and 1 Billion for 2024. But they took it out. They have not given any guidance for 2023 yet. Only 25-30 Million for this year. Why not leave that in the presentation if they still expected those numbers?

Even with 81 Million that is 117 Million total cash. That's only 3 quarters with their cash burn.

They said their platform was completed two years early. What if it wasn't? This company would be dead in the water.

We can only hope this saves them.

Baseline Band Design Confirmed – With plans to begin production in the second half of 2022, the Company finalized the design of its new Baseline band and began finalizing agreements with its contract manufacturers, building its supply chain and ecosystem as it moves to production. Initial shipments of Rockley’s Baseline band to customers are expected in the fourth quarter of 2022.

[prototype_101]

Outlook for Fiscal Year 2022 Revenue $20 - $30 million

ok so 1 million Revenue in Q1 so think about how parabolic the Revenue ramp is EVEN in 2022

[prototype_101]

I think you are being short sighted, they are still planning 300+ million revenue IMO based on ACCELERATION in health sensing products investors have been told ewvery time, right?

[prototype_101]

I think the problem is not delay to market with any of the health sensing, I think it is the lack of cash they were suppose to get over 50 million from sale of comm business unit to Chinese that regulators thwarted, right?

[Bruinfan4ever]

Only 1 Million in Rev? Cash went from 81 Million down to 36 Million. Just all around ugly. This financing pretty much saved them from bankruptcy. 81 Million in cash. Can they be profitable in 2 or 3 more quarters?

What a damn shame if this company can't make it with this technology.

[Bruinfan4ever]

They originally said they had enough to make it to market. So I am not sure we can believe the original forecast of 400 Million next year.

But part of the 81 Million is paying off 24 Million in debt. So that will be like 2 more quarters of cash. So hopefully they are right around the corner of Profitability.

[Bruinfan4ever]

.

[Bruinfan4ever]

Any comments on the financing deal?

[Bruinfan4ever]

NEWS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

https://investors.rockleyphotonics.com/news/news-details/2022/Rockley-Photonics-Announces-Results-of-Preliminary-Human-Study-Measuring-Hydration-and-Introduces-a-Novel-Hydration-Index/default.aspx

[Bruinfan4ever]

That article is kind of strange. It sounds like Apple is trying to do things on their own but then says they have a deal with Rockley.

[IBB-99]

Apple would be nice, as long as they pay their "fair share"

[IBB-99]

https://www.idc.com/promo/wearablevendor

[IBB-99]

Here are the top health tech companies and startups developing wearable medical devices in 2022

https://www.insiderintelligence.com/insights/wearable-tech-companies-startups/

[IBB-99]

Apple Watch Series 8 Rumors:

https://www.macrumors.com/guide/apple-watch-series-8/#:~:text=Apple%20supplier%20Rockley,at%20some%20point.

[Bruinfan4ever]

It's got to be Apple, right? Who would get it before Apple?

[prototype_101]

Rockley Photonics Announces Shipment of VitalSpex™ Pro Biosensing Technology for Alcohol, Lactate, and Glucose Measurement
May 04 2022 - 09:05AM
Business Wire

Rockley Photonics Holdings Limited (NYSE: RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced it has shipped its VitalSpex™ Pro technology for the non-invasive measurement of alcohol, glucose, and lactate to an early-access, tier-1 consumer wearables customer. The shipment of this advanced biomarker-sensing technology marks an important milestone in the progress of next-generation digital healthcare.

“Shipping the enhanced, higher-performance Pro version of our VitalSpex biosensing platform is an important step forward for the future of the digital health category,” said Dr. Andrew Rickman, chairman and chief executive officer of Rockley. “We believe that the ability to continuously monitor an expanded range of biomarkers will be a game-changer. Our customer’s ability to integrate our biosensing technology into smart wearables has the potential to transform health outcomes by enabling earlier detection of certain conditions and improving the management and treatment of illnesses such as hypertension, liver disease, or diabetes. With these advances, practitioners like Dr. David Klonoff, clinical professor of medicine at the University of California, San Francisco, increasingly understand that the important insights gained from continuously monitoring multiple biomarkers provide a holistic view of an individual’s health.”

Rockley intends to begin production of the Baseline version of its VitalSpex biosensing platform, which will measure biomarkers for blood oxygen, blood pressure, body hydration, core body temperature, heart rate, heart rate variation, and respiratory rate, in the second half of 2022. The Company plans to begin production of the Pro version of its VitalSpex biosensing platform in 2023, which will measure an extended range of biomarkers, including alcohol, glucose, and lactate.

More information about Rockley’s digital health monitoring solution is available here: https://rockleyphotonics.com/biomarker-sensing

About Rockley Photonics

A global leader in photonics-based health monitoring and communications solutions, Rockley Photonics is developing a comprehensive range of photonic integrated circuits and associated modules, sensors, and full-stack solutions. From next-generation sensing platforms specifically designed for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications across multiple industries. Rockley believes that photonics will eventually become as pervasive as micro-electronics, and it has developed a platform with the power and flexibility needed to address both mass markets and a wide variety of vertical applications.

Formed in 2013, Rockley is uniquely positioned to support hyper-scale manufacturing and address a multitude of high-volume markets. Rockley has partnered with numerous tier-1 customers across a diverse range of industries to deliver the complex optical systems required to bring transformational products to market.

To learn more about Rockley, visit rockleyphotonics.com.

https://ih.advfn.com/stock-market/NYSE/rockley-photonics-RKLY/stock-news/88008309/rockley-photonics-announces-shipment-of-vitalspex

[Bruinfan4ever]

NEWS!!!!!!!!!

https://investors.rockleyphotonics.com/news/news-details/2022/Rockley-Photonics-Announces-Shipment-of-VitalSpex-Pro-Biosensing-Technology-for-Alcohol-Lactate-and-Glucose-Measurement/default.aspx

[Bruinfan4ever]

Thanks. I did not realize there was a gap. And a gap will most certainly get filled in these market conditions.

[prototype_101]

the 2.80 to 2.84 gap left 1/28/22 was filled today, it was on that date 1/28/22 that the PPS bottomed at 2.52, so I'm thinking today marks the gap filling double bottom and the PPS starts moving up from these ridiculously oversold levels, and yes, the early revenue guidance Rkly gave was for 2023 between 300-400 million, and for 2024 to be over 1 billion, and I can't imagine those numbers not being higher now with the additional customers announced, and the 2 year acceleration of one product

with today's PPS, the market cap sits at 1x 2023 sales and less than 0.5x 2024 sales, that's INSANE!!

[Bruinfan4ever]

It's obvious the market doesn't believe the CEO. If the market believed there would be 1 Billion in Rev by 2024, the stock would be 20+ easy.

The market also may not be kind to the delay of earnings. Why not just PR the news on the trial, or the record shipping? Those are great PR's that could be released to help the stock price.

There better be some really good news in that earnings call they decided to delay.

[Bruinfan4ever]

Earnings Revised to May 12th.
They want to discuss

“By revising our earnings date, we expect to be able to share additional information on our earnings call that we are still reviewing; for example, the preliminary results from our human study on hydration and a new product shipment milestone,” said Dr. Andrew Rickman, chairman and chief executive officer of Rockley.

New product shipping milestone? Can't wait for that.

.

On the upcoming call, the Company plans to discuss the following topics –

Biotpx healthcare biomarker sensing platform, launched two years early, which includes its wearable band, cloud analytics and AI, and product samples were shipped to multiple customers in the first quarter;
VitalSpex consumer device samples continue to ship to customers in 2022;
Timeline for the shipment of its Baseline, including core body temperature, hydration and blood pressure biomarkers, continues to be expected in the second half of 2022;
Timeline for shipment of its Pro, including alcohol, glucose and lactate, continues to be expected to ship approximately six months after its Baseline; and
Rockley’s expanded customer base, which includes companies like Medtronic, has made the Company less reliant on any one customer.

[SteveSchiets]

None taken Proto.
Ive learned that Mr Market can be a total dick. And i was simply hoping for such a brief moment.

I bought RKLY based on these revenues figures at 11$. It can go back up now.

[prototype_101]

> Biotpx healthcare biomarker sensing platform, launched two years early, which includes its wearable band, cloud analytics and AI, and product samples were shipped to multiple customers in the first quarter

> VitalSpex consumer device samples continue to ship to customers in 2022

> Timeline for the shipment of its Baseline, including core body temperature, hydration and blood pressure biomarkers, continues to be expected in the second half of 2022

> Timeline for shipment of its Pro, including alcohol, glucose and lactate, continues to be expected to ship approximately six months after its Baseline

> Rockley’s expanded customer base, which includes companies like Medtronic, has made the Company less reliant on any one customer.

Rockley Photonics (NYSE: RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced that its first quarter 2022 financial results conference call has been rescheduled to after the market close on Thursday, May 12, 2022, to allow additional time to prepare its earnings report. The Company plans to host a conference call that day at 5:00 p.m. Eastern Time to review its financial results and business outlook.

“By revising our earnings date, we expect to be able to share additional information on our earnings call that we are still reviewing; for example, the preliminary results from our human study on hydration and a new product shipment milestone,” said Dr. Andrew Rickman, chairman and chief executive officer of Rockley.

https://ih.advfn.com/stock-market/NYSE/rockley-photonics-RKLY/stock-news/87908038/rockley-photonics-revises-date-of-first-quarter-20

[prototype_101]

no offense Steve, but your target was insane, Rkly has already shown Revenue guidance for 2023 over 300 mil and 2024 over 1 billion, and since then they have told investors nothing but good news on new large customers like Medtronic, and a 2 year acceleration of expected Revenues on certain product, this stock is being held down for Accumulation purposes by the M-team, it should at a minimum be a 1 billion market cap today, that's a PPS over $8

[SteveSchiets]

Looks like my price target failed. I was hoping for cheaper prices but the market thinks I’m wrong. No problem. Go RKLY

[IBB-99]

Added shares below 3 today and chart closed with a bullish reversal hammer on higher volume.